🇺🇸 FDA
Patent

US 10030024

Imidazopyridazines useful as inhibitors of the PAR-2 signaling pathway

granted A61PA61P1/02A61P1/04

Quick answer

US patent 10030024 (Imidazopyridazines useful as inhibitors of the PAR-2 signaling pathway) held by Vertex Pharmaceuticals Incorporated expires Mon Jul 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Jul 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61P, A61P1/02, A61P1/04, A61P11/06, A61P17/00